Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.
Addressing a significant medical problem. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age.
Superior, patented design. The technology is a minimally invasive device, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Covered by 18 U.S. patents with 393 allowed claims, the technology is designed to overcome the significant shortcomings of first-generation ELGs.
Compelling clinical data. There is a significant reduction in blood loss, operative time, Intensive Care Unit (ICU) utilization and hospital length of stay for Powerlink patients when compared with traditional open surgical repair for AAA. Also, on-going clinical study results show there is a lower mortality for Powerlink patients than in open surgical repair patients.
Seasoned management team. The executive management team has a record of building shareholder value with over 175 years of combined medical device experience and a strong record of success with medical products.
View all news releasesRECENT RELEASES
Dec 5, 2013
Dec 3, 2013
Nov 25, 2013